Synairgen (SYN) AGM Report

The Synairgen 2019 AGM was held on Monday 2nd June at the offices of Fladgate LLP, 16 Great Queen Street, London.

For anyone who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO; the most recent was in Sept 2018 to raise £2.9 million through the issue of around 18M ordinary Shares at a price of 16p/share (a discount of around 11%). The shares currently trade at around 13p/share valuing Synairgen at about £14m.

The company broker Finncap currently have a price target of…

Click here for the complete AGM report if you are a full member of ShareSoc, as these reports are exclusive to our full members. The above is only an introduction to the full report, which contains much more information. Further information about access to our AGM reports can be found here.